Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Albanell

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)|July 26, 2000
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancerJ Bellmunt, V Guillem, L Paz-Ares, et al.
Oncogene|January 10, 2017
CIP2A confirms its prognostic value in triple-negative breast cancerI Cristóbal, S Zazo, B Torrejón, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensityA Ribas, J Albanell, J Bellmunt, et al.
Oncology|August 28, 2004
Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapyM Martin-Richard, M Muñoz, J Albanell, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 24, 2017
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of PathologyR Colomer, I Aranda-López, J Albanell, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 20, 2018
Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of PathologyR Colomer, I Aranda-López, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancerJ Carles, E Esteban, M Climent, et al.
Anticancer Research|March 1, 1996
Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosisJ Albanell, J Bellmunt, R Molina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2005
Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patientsA Sanjuàn, S Vidal-Sicart, G Zanón, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancerA D Seidman, C A Hudis, J Albanell, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
European Journal of Cancer (Oxford, England : 1990)|July 26, 2000
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancerJ Bellmunt, V Guillem, L Paz-Ares, et al.
Oncogene|January 10, 2017
CIP2A confirms its prognostic value in triple-negative breast cancerI Cristóbal, S Zazo, B Torrejón, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1996
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensityA Ribas, J Albanell, J Bellmunt, et al.
Oncology|August 28, 2004
Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapyM Martin-Richard, M Muñoz, J Albanell, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 24, 2017
Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of PathologyR Colomer, I Aranda-López, J Albanell, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 20, 2018
Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of PathologyR Colomer, I Aranda-López, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancerJ Carles, E Esteban, M Climent, et al.
Anticancer Research|March 1, 1996
Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosisJ Albanell, J Bellmunt, R Molina, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 26, 2005
Clinical axillary recurrence after sentinel node biopsy in breast cancer: a follow-up study of 220 patientsA Sanjuàn, S Vidal-Sicart, G Zanón, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 21, 1998
Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancerA D Seidman, C A Hudis, J Albanell, et al.
Pageof 10